Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany
# Background About 400,000-500,000 people are infected with hepatitis C in Germany. Long-term consequences are the development of liver cirrhosis and hepatocellular carcinoma. The introduction of first generation protease inhibitors has significantly improved the treatment of hepatitis C genotype 1...
Saved in:
| Main Authors: | Jona T. Stahmeyer, Svenja Schauer, Siegbert Rossol, Hans Heinrich Wedemeyer, Daniel Wirth, Florence Bianic, Christian Krauth |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2013-12-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://jheor.org/article/9870-cost-effectiveness-of-triple-therapy-with-telaprevir-for-chronic-hepatitis-c-virus-patients-in-germany |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study
by: T. Berg, et al.
Published: (2019-01-01) -
Review of Boceprevir and Telaprevir for the Treatment of Chronic Hepatitis C
by: Kyle J Wilby, et al.
Published: (2012-01-01) -
Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naïve Genotype 1b Chronic Hepatitis C Patients
by: Hiroshi Abe, et al.
Published: (2014-01-01) -
Chronic Hepatitis C Therapy in Liver Cirrhosis Complicated by Telaprevir-Induced DRESS
by: Omar Y. S. Mousa, et al.
Published: (2014-01-01) -
Comparative analysis of the safety of triple therapy with telaprevir between HCV monoinfected and HIV coinfected patients
by: C. Sangrador Pelluz, et al.
Published: (2014-01-01)